Skip to search formSkip to main contentSkip to account menu

palonosetron

Known as: (3aS)-2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a, 4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, Palonosetronum, palonosetron [Chemical/Ingredient] 
The active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. Palonosetron is a type of serotonin receptor antagonist… 
National Institutes of Health

Related topics

Related topics

10 relations
5 ML palonosetron 0.05 MG/ML Injection [Aloxi]Serotonin 3 Receptor Antagonists [MoA]netupitant / palonosetronnetupitant 300 MG / palonosetron 0.5 MG Oral Capsule [Akynzeo]

Narrower (3)

AloxiPalonosetron hydrochlorideRS 25259

Broader (3)

IsoquinolinesQuinuclidinesSerotonin Antagonists

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future Perspectives
Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first appearance in 1947. ZIKV reappeared after… 
Review
2012
Review
2012
Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.
Highly Cited
2011
Highly Cited
2011
A Randomized, Double-Blind Trial of Palonosetron Compared with Ondansetron in Preventing Postoperative Nausea and Vomiting after Gynaecological Laparoscopic Surgery
This randomized, double-blind study evaluated the relative efficacy of palonosetron (a new, selective 5-hydroxytryptamine type 3… 
Highly Cited
2010
Highly Cited
2010
Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
Review
2009
Review
2009
Palonosetron
SummaryAbstractPalonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile… 
Highly Cited
2008
Highly Cited
2008
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Different Doses of Palonosetron Versus Placebo for Preventing Postoperative Nausea and Vomiting
BACKGROUND: In this randomized, double-blind study we assessed the efficacy and safety of three different doses of the 5-HT3… 
Highly Cited
2007
Highly Cited
2007
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer
Goals of workThe aims of this study were to assess the safety and antiemetic efficacy of multiple-day dosing of palonosetron plus… 
Review
2005
Review
2005
Delayed emesis: moderately emetogenic chemotherapy
Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy… 
Highly Cited
2004
Highly Cited
2004
Pharmacokinetic and Safety Evaluation of Palonosetron, a 5‐Hydroxytryptamine‐3 Receptor Antagonist, in U.S. and Japanese Healthy Subjects
Palonosetron (Aloxi™, Onicit®) is a selective 5‐HT3 receptor antagonist recently approved by the Food and Drug Administration for… 
Review
2003
Review
2003
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis
Palonosetron (Aloxi™) is a 5-HT3-receptor antagonist antiemetic indicated for the prevention of acute and delayed nausea and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)